Grazoprevir/Elbasvir
PreclinicalSmall molecule
Merck & Co.Grazoprevir/Elbasvir is one of 6 small molecule programs targeting Resectable. It is currently in Preclinical.
1
Indications
8
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Resectable
#DrugCompanyPhaseTrials
1BL-B01D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 2
Almonertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 2
CEB-01
BioMarin PharmaceuticalPhase 2
PD-L1 Inhibitor
BBuzzard Pharmaceuticals
Phase 2
Qinlock
DDeciphera Pharmaceuticals, LLC
Preclinical
Grazoprevir/Elbasvir
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatitis C3 trials
Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4
Completed·IInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba·Phase 2·NCT02886624·30 enrolled
Resectable1 trial
Efficacy and Safety1 trial
Chronic Hepatitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Grazoprevir/Elbasvir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company